Skip to content
Study details
Enrolling now

EUS RFA for Pancreatic Cancer

NYU Langone Health
NCT IDNCT05723107ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

15

Study length

about 5 years

Ages

18+

Locations

1 site in NY

What this study is about

This trial is testing the safety and tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) in people with pancreatic cancer who are not candidates for surgery. The treatment uses a device to deliver heat to cancerous cells.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Chemotherapy
  • 2.Use Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0

Secondary: Disease-Free Survival from Diagnosis, Disease-Free Survival from First Study Procedure, Overall Survival From Diagnosis

Body systems

Oncology